Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161590 · ClinicalTrials.gov registry record · Phase 1
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
A Phase 1 study of T-Cell Lymphoma and Lymphoma, Non-Hodgkins, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00161590 is a Phase 1 study of T-Cell Lymphoma and Lymphoma, Non-Hodgkins that has completed, run by Weill Medical College of Cornell University. The trial reports 1 study location across 1 state.
The verdict
NCT00161590, a Phase 1 study of T-Cell Lymphoma and Lymphoma, Non-Hodgkins, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
Primary Objective: * To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (C-CHOP) in patients with T-cell, null-cell and NK-cell lymphomas. Secondary Objectives: * To evaluate response rate, overall survival, and disease-free survival in patients with T-cell, null-cell, and NK-cell lymphomas treated with Campath + CHOP chemotherapy. * To assess the incidence of cytomegalovirus (CMV) reactivation in patients with these lymphomas treated with the Campath + CHOP combination. * To determine features which might be predictive of resistance to treatment or predictive of relapse, including the absence of glycosylphosphatidylinositol (GPI)-linked proteins.
Conditions Studied
Interventions
- DRUG CHOP and alemtuzumab
Study Locations (1)
New York
- Weill Medical College of Cornell University - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00161590
The ClinicalTrials.gov registry entry for NCT00161590 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CHOP and alemtuzumab is the first listed.
NCT00161590 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00161590 about?
NCT00161590 is a clinical study titled "Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma". Primary Objective: * To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (C-CHOP) in patients with T-cell, null-cell and NK-cell lymphomas. Secondary Objecti...
What is the current status of trial NCT00161590?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-07.
What conditions does trial NCT00161590 study?
This clinical trial studies the following conditions: T-Cell Lymphoma, Lymphoma, Non-Hodgkins.
What interventions are being tested in trial NCT00161590?
The interventions under investigation include: CHOP and alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT00161590?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00161590 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Study of Tazemetostat in Lymphoid Malignancies
RECRUITING · Phase 1
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CD4CAR for CD4+ Leukemia and Lymphoma
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.